

REMARKS

Applicant thanks the Examiner for the interview of April 2, 2008 in which the Examiner proposed certain amendments to place the claims in condition for allowance. Applicant hereby submits amendments to the claims which have been mutually agreed upon by Applicant's representative and the Examiner. The amendments are supported in the application as follows. Disclosure of a B7RP-1 polypeptide of SEQ ID NO: 7 "comprising a mature amino terminus at residue 47" is found at p. 6, lines 10-12 of the specification and original Claim 12; disclosure of a B7RP-1 polypeptide of SEQ ID NO: 12 or 17 "comprising a mature amino terminus at any of residues 19, 20, 21, 22, 24 or 28" is found at p. 6, lines 12-16 of the specification and original Claim 12; and disclosure of "a fragment [thereof] comprising at least about 25, 50, 75, 100 or greater than 100 amino acid residues" of a B7RP-1 polypeptide of SEQ ID NO: 12 or 17 is found at p. 6, lines 17-21 specification and original Claim 12.

It is believed that the claims are in immediate condition for allowance. Accordingly, the Examiner is respectfully requested to pass this application to issue. The Examiner is respectfully requested to contact Applicant's undersigned representative to address any unresolved issues remaining in the application.

Respectfully submitted,



Robert B. Winter
Attorney/Agent for Applicant(s)
Registration No.: 34,458
Phone: (805) 447-2425
Date: April 15, 2008

Please send all future correspondence to:
21069
US Patent Operations/RBW
Dept. 4300, M/S 28-2-C
AMGEN INC.
One Amgen Center Drive
Thousand Oaks, California 91320-1799